PI3K-Akt-mTOR
The PI3K/AKT/mTOR signaling pathway is strongly involved in the fundamental cellular processes of protein synthesis and apoptosis, and disturbed activation of this intracellular pathway has been associated with the development of diseases such as cancer, diabetes mellitus, and autoimmunity[1]. Upon activation of phosphatidylinositol (PI)-3-kinase (PI3K) by extracellular growth factors, phosphorylation of the inner membrane phosphoinositides activates AKT (also known as Protein Kinase B, PKB) and PDPK1 (3-phosphoinositide dependent protein kinase-1). In turn, mTOR (mammalian target of rapamycin) is activated downstream, which plays an important role in cell cycle progression[2]. In many cancer cells, this PI3K/AKT/mTOR pathway is highly active, which can be the result of amplification or mutation of the PI3-kinase gene; amplification or mutation of the Akt gene; or loss of function of PTEN (Phosphatase and tensin homolog). The latter normally regulates the removal of phosphate groups of the PI3K mediated phosphorylated membrane phospholipids, one of the regulating mechanisms to prevent over activations of this pathway.
[1] PI3K-Akt pathway: its functions and alterations in human cancer. Osaki M, Oshimura M, Ito H. Apoptosis 2004, 9, 667-676.
[2] PI3K/Akt/mTOR pathway as a target for cancer therapy. D. Morgensztern, H.L. McLeod Drugs 2005, 16, 797–803
Axon ID | Name | Description | From price | |
---|---|---|---|---|
1909 | A 1070722 | Selective inhibitor of GSK-3 | €95.00 | |
1831 | A 66 | PI3K inhibitor (p110-α specific) | €95.00 | |
1466 | A 769662 | AMPK activator | €85.00 | |
2857 | Acalisib | PI3K inhibitor (p110 δ specific) | €120.00 | |
3590 | ACT001 | PAI-1 inhibitor | €210.00 | |
2275 | AdipoRon | Orally active small-molecule AdipoR agonist | €80.00 | |
2389 | AICAR | Potent AMPK activator and inducer of differentiation of NSCs | €45.00 | |
2540 | Akt Inhibitor VIII | Inhibitor of Akt1 and 2 with significant off-side effects (CaMKIα and AhR) | €95.00 | |
2925 | Alpelisib | PI3K inhibitor (p110-α specific) | €90.00 | |
3827 | AMG-511 | Orally bioavailable, highly potent and selective pan-class I phosphatidylinositol-3 kinase (PI3K) inhibitor | Inquire | |
2368 | Amuvatinib | RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met | €105.00 | |
3328 | APIO-EE-07 | Dual RSK1/MSK2 inhibitor | €140.00 | |
2167 | AR-A 014418 | ATP-competitive GSK-3 inhibitor | €85.00 | |
3041 | ARN 3236 | Potent, selective, ATP-competitive, and orally available inhibitor of SIK2 | €80.00 | |
3837 | ARUK2001607 | Potent, selective, and brain-penetrant PI5P4Kγ inhibitor | €120.00 | |
1424 | AS 252424 | PI3K inhibitor (p110-γ specific) | €85.00 | |
1436 | AS 252424 bispotassium salt | PI3K inhibitor (p110-γ specific) | €95.00 | |
2166 | AT 13148 dihydrochloride | ATP-competitive inhibitor of multi-AGC kinases | €70.00 | |
2748 | Autophinib | PIK3C3/Vps34 inhibitor | €120.00 | |
5051 | Axon Ligands™ Cell signaling and Oncology compound library | Axon Ligands™ Cell signaling and Oncology compound library | Inquire | |
5053 | Axon Ligands™ Stem cell compound library | Axon Ligands™ Stem cell compound library | Inquire | |
2345 | AZ 20 | Potent, orally active and selective inhibitor of ATR protein kinase | €105.00 | |
2171 | AZD1080 | Selective inhibitor of GSK-3α and GSK-3β | €90.00 | |
3996 | AZD2014 | Orally bioavailable dual mTORC1/mTORC2 inhibitor | Inquire | |
3771 | AZD2858 | Potent and highly selective Glycogen Synthase Kinase-3β inhibitor | €95.00 | |
2194 | AZD2858 hydrochloride | Potent and highly selective Glycogen Synthase Kinase-3β inhibitor | €95.00 | |
3808 | AZD3458 | Orally bioavailable potent and selective PI3Kγ inhibitor | Inquire | |
1859 | AZD5363 dihydrochloride | Inhibitor of protein kinase B (Akt) | €90.00 | |
2926 | AZD6482 | PI3K inhibitor (p110 β specific) | €120.00 | |
3134 | AZD6738 | Potent, selective, orally active and bioavailable ATR kinase inhibitor | €110.00 |